{"denoms":[{"counts":[{"groupId":"BG000","value":"18"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous daratumumab at 16 mg/kg on the same dosing schedule (weekly, every 2 weeks, or every 4 weeks of each 28-day treatment cycle) on their last prior therapy containing daratumumab regimen. The dosing schedule for daratumumab could be adjusted during the course of the study, provided the participant had a response of stable disease or better. Participants also received IV durvalumab at 1500 mg on Day 2 of Cycle 1 and then on Day 1 of Cycles ≥ 2 of each 28-day treatment cycle. Participants could continue on study treatment until progressive disease or unacceptable toxicity.","id":"BG000","title":"Daratumumab and Durvalumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.41","value":"62.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Not Collected or Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}],"title":"0 = Fully Active"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"1 = Restrictive but ambulatory"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"2 = Ambulatory but unable to work"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"3 = Limited Self-Care"}]}],"description":"ECOG PS is used by physicians and researchers to assess how a subject's disease is progressing, and how the disease affects the daily living activities and determine appropriate treatment and prognosis. 0 = Fully Active, able to carry on all pre-disease performance without restriction; 1 = Restricted, in physically strenuous activity but ambulatory; 2 = Ambulatory and capable of all self-care; unable to carry out work activities. 3 = Capable of only limited self-care, confined to bed or chair \\>50% of waking hours 4 = Completely Disabled, cannot carry on any self-care 5 = Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Missing"}]}],"description":"The International Staging System divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Stage I: Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L); Stage II: Neither stage I or III, meaning that either: # The beta-2 microglobulin level is between 3.5 and 5.5 (with any albumin level), OR # The albumin is below 3.5 while the beta-2 microglobulin is less than 3.5 Stage III: Serum beta-2 microglobulin is greater than 5.5.","paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System Multiple Myeloma Stage at Entry","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"3","upperLimit":"16","value":"4.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number of Prior Regimens","unitOfMeasure":"Regimens"}],"populationDescription":"Full Analysis Population = all participants who enrolled in the study."}